At ASH, drugmakers to showcase early data for three-pronged cancer therapies
J&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment for multiple myeloma.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.